Arndt Vogel

Arndt Vogel is a leading European expert in biliary tract cancers and hepatocellular carcinoma clinical research. He contributed to the TOPAZ-1 trial investigating durvalumab plus gemcitabine-cisplatin chemotherapy in advanced biliary tract cancers, demonstrating improved overall survival that established immunotherapy combinations as a new standard of care in this disease. He has evaluated multiple systemic therapy combinations in cholangiocarcinoma and hepatocellular carcinoma clinical trials. His translational research has investigated molecular predictors of response to immunotherapy in biliary tract cancers including TMB, PD-L1 expression, and MSI status.